For the Inventor, By the Inventor

Enter assignee name

Epalinges, Switzerland

Adc Therapeutics Sa

USPTO Granted Patents = 21

CIPO Patents = 47

EPO Patents = 21

Trademarks = 11

Forward Citations = 37

Loading Chart...

Loading Chart...

52 inventors (with patents filed for the assignee):

Patricius Hendrikus Cornelis Van Berkel (13 out of 24 patents)

Philip Wilson Howard (8 out of 92 patents)

Jay Marshall Feingold (4 out of 4 patents)

4. Gilles Bernard Tremblay (4 out of 29 patents)

5. Mario Filion (4 out of 26 patents)

6. Traian Sulea (3 out of 32 patents)

7. Anna N Moraitis (3 out of 6 patents)

8. John Hartley (3 out of 4 patents)

9. Jens Wuerthner (3 out of 3 patents)

10. David Rodney Ungar (2 out of 2 patents)

11. Francesca Zammarchi (2 out of 2 patents)

12. Patricius Henrikus Cornelis Van Berkel (1 out of 2 patents)

13. Lisa Skelton (1 out of 1 patent)

14. Francois Bertelli (1 out of 1 patent)

15. Francesco Bertoni (6 patents)

21 patents: Sort by Forward Citations

1. 11976122 - Anti-IL13Rα2 antibodies (2024-05-07),

2. 11938192 - Dosage regimes for the administration of an anti-CD19 ADC (2024-03-26),

3. 11813335 - Pyrrolobenzodiazepine-antibody conjugates (2023-11-14),

4. 11702473 - Site-specific antibody-drug conjugates (2023-07-18),

5. 11690918 - Pyrrolobenzodiazepine-anti-CD22 antibody conjugates (2023-07-04),

6. 11596696 - Combination therapy with an anti-CD25 antibody-drug conjugate (2023-03-07),

7. 11426467 - Dosage regimes for the administration of an anti-CD25 ADC (2022-08-30),

8. 11384098 - Pyrrolobenzodiazepine-antibody conjugates (2022-07-12),

9. 11318211 - Dosage regimes for the administration of an anti-CD19 ADC (2022-05-03),

10. 11160872 - Pyrrolobenzodiazepine-antibody conjugates (2021-11-02),

11. 11084872 - Method for treating breast cancer (2021-08-10),

12. 10799596 - Pyrrolobenzodiazepine-antibody conjugates (2020-10-13),

13. 10780096 - Pyrrolobenzodiazepine-antibody conjugates (2020-09-22),

14. 10722594 - Pyrrolobenzodiazepine-anti-CD22 antibody conjugates (2020-07-28),

15. 10597450 - Antibodies against kidney associated antigen 1 and antigen binding fragments thereof (2020-03-24),

ADC Therapeutics SA is a clinical-stage oncology-focused biotechnology company pioneering the development of highly targeted antibody drug conjugates (ADCs) for treating both solid tumors and hematological malignancies. The company's proprietary technology uses monoclonal antibodies to deliver potent cytotoxic agents directly to cancer cells, thereby minimizing systemic exposure to toxic payload while maximizing therapeutic efficacy. ADC Therapeutics is committed to translating its innovative ADC platform into novel cancer therapies to address the significant unmet medical needs of patients worldwide.

This text is generated by artificial intelligence and may not be accurate.

Company Badge

USPTO Data Jan 1 1976 - Dec 9 2025

21 Patents

#2 in Epalinges

#567 in Switzerland

#29,031 in the World

Epalinges, Switzerland

Adc Therapeutics Sa

Forward Citations = 37

52 inventors:

Patricius Hendrikus Cornelis Van Berkel (13 out of 24 patents)

Philip Wilson Howard (8 out of 92 patents)

Jay Marshall Feingold (4 out of 4 patents)

4. Gilles Bernard Tremblay (4 out of 29 patents)

5. Mario Filion (4 out of 26 patents)

Please report any incorrect information to support@idiyas.com

Loading…